IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.840
NA - Nord America 1.782
AS - Asia 551
SA - Sud America 3
OC - Oceania 2
AF - Africa 1
Totale 4.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.777
IE - Irlanda 528
SE - Svezia 392
PL - Polonia 299
CN - Cina 258
IT - Italia 231
SG - Singapore 223
UA - Ucraina 102
GB - Regno Unito 94
DE - Germania 65
FI - Finlandia 64
VN - Vietnam 24
BE - Belgio 20
FR - Francia 16
IN - India 15
ID - Indonesia 13
RU - Federazione Russa 11
NL - Olanda 10
IR - Iran 4
JP - Giappone 4
AT - Austria 3
CA - Canada 3
IL - Israele 3
JO - Giordania 3
BR - Brasile 2
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
HK - Hong Kong 1
LI - Liechtenstein 1
LV - Lettonia 1
MA - Marocco 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
TH - Thailandia 1
TW - Taiwan 1
Totale 4.179
Salva come PNG Salva come JPEG
Città #
Dublin 528
Chandler 404
Warsaw 299
Nyköping 239
Singapore 185
Jacksonville 160
Messina 120
Ashburn 111
Dearborn 94
Princeton 82
Beijing 74
Medford 72
Ann Arbor 58
Des Moines 58
Cambridge 51
Lancaster 49
Houston 35
Wilmington 34
Boardman 33
Woodbridge 28
Jinan 25
Dong Ket 24
San Mateo 23
Seattle 22
Shenyang 22
New York 19
Brussels 18
Falls Church 18
Los Angeles 17
Munich 15
Helsinki 14
Jakarta 13
Nanchang 12
Ningbo 12
Nanjing 11
Haikou 8
Zhengzhou 8
Kunming 7
Rome 7
Auburn Hills 6
Fairfield 6
Guangzhou 6
Hangzhou 6
Pune 6
Redwood City 6
Taizhou 6
Tianjin 6
Chengdu 5
Hyderabad 5
Jiaxing 5
Milan 5
Norwalk 5
Piazza Armerina 5
Washington 5
Cagliari 4
Changsha 4
Edinburgh 4
Hebei 4
Kyoto 4
Nuremberg 4
Amman 3
Gaithersburg 3
Lappeenranta 3
London 3
Recanati 3
Santa Clara 3
Scarsdale 3
Vienna 3
Amsterdam 2
Ardabil 2
Bologna 2
Castrolibero 2
Charlottesville 2
Chicago 2
Clearwater 2
Florence 2
Foggia 2
Gela 2
Genoa 2
Hefei 2
Joinville 2
Monmouth Junction 2
Mountain View 2
Ottawa 2
Saint Petersburg 2
San Giovanni La Punta 2
San Pietro Clarenza 2
Strasbourg 2
Taiyuan 2
Tappahannock 2
Waanrode 2
Andover 1
Atlanta 1
Auckland 1
Augusta 1
Bangkok 1
Baotou 1
Berlin 1
Bremen 1
Brno 1
Totale 3.195
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 229
Kinase regulation of human MHC class i molecule expression on cancer cells 112
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 107
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 101
Emerging markers of cachexia predict survival in cancer patients. 93
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 90
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 84
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 79
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations 79
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 73
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 72
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 71
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 70
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 70
Originator Erythropoietin Alpha Vs Biosimilar Erythropoietin Alpha vs Erythropoietin Zed Plus Liposomial Iron and b12 and Folates in Patients with Refractory Anemia. Five Center Retrospective Study 69
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 68
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 68
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 67
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 66
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 65
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 65
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 65
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 65
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 64
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 63
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 62
Thyroid function, autoimmunity and nodules in hematological malignancies 61
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 60
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 60
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 60
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 59
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 58
Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study 58
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 58
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 58
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 58
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 57
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 57
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma 57
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 56
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 55
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 55
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 53
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 52
Congenital heart disease in down syndrome 51
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 50
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 50
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 49
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 49
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 49
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 48
R-CHOP versus R-COMP: are they really equally effective? 48
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 48
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 47
The heart in Anderson-Fabry disease 47
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 46
null 46
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 45
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death 43
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 42
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 41
Emerging drugs for diffuse large B-cell lymphoma. 39
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 39
Primary central nervous system lymphoma: Novel precision therapies 38
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 36
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 35
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 32
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 28
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma 28
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 26
Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma. 25
Pim kinases in hematological malignancies: where are we now and where are we going? 24
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 24
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 24
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 22
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 16
Insights into the tumor microenvironment of B cell lymphoma 12
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 9
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 7
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 6
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 6
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma 5
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma 3
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 3
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 3
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments 3
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation 3
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 3
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 2
Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy 2
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia 2
Totale 4.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020358 0 0 0 0 0 82 89 50 21 44 59 13
2020/2021650 66 22 118 29 79 40 40 80 54 70 20 32
2021/2022553 3 44 19 19 30 19 20 19 8 101 65 206
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/2025347 14 19 34 118 103 59 0 0 0 0 0 0
Totale 4.453